Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GlaxoSmithKline plc
Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.
Accelerated Approval Makes Big Splash In 2021 Novel Agents, Despite Crackdown On ‘Dangling’ Cancer Claims
US FDA’s accelerated approvals hit a contemporary high in 2021, accounting for one-third of novel US approvals, but the big story was the agency’s crackdown on delinquent confirmatory trials for oncology AA indications.
Unilever, which has had three offers for GSK rebuffed, likely notes that the Federal Trade Commission and Department of Justice signal they will tighten scrutiny of deals that merge companies providing consumer-facing products and services.
- Other Names / Subsidiaries
- ABR Development
- Corixa Corporation
- Fountain Acquisition Corporation
- Genelabs Technologies, Inc.
- GlycoVaxyn AG
- Human Genome Sciences, Inc.
- ID Biomedical Corporation
- Okairos AG
- PRAECIS Pharmaceuticals, Inc.
- Reliant Pharmaceuticals
- Sirtris Pharmaceuticals
- Sitari Pharmaceuticals, Inc.
- SmithKline Beecham
- Stiefel Laboratories, Inc.
- Tesaro, Inc.
- ViiV Healthcare